Differential Expression of Stem Cell Markers in Human Adamantinomatous Craniopharyngioma and Pituitary Adenoma

Imagem de Miniatura
Arquivos
art_CHANG_Differential_Expression_of_Stem_Cell_Markers_in_Human_2017.PDF (1.23 MB)
Citações na Scopus
18
Tipo de produção
article
Data de publicação
2017
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
KARGER
Autores
ARAUJO, Ricardo Vieira
CIRQUEIRA, Cinthya Santos
CANI, Carolina Maria Gomes
Citação
NEUROENDOCRINOLOGY, v.104, n.2, p.183-193, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background/Aims: Although craniopharyngioma (CP) is histologically benign, it is a pituitary tumour that grows rapidly and often recurs. Adamantinomatous CP (ACP) was associated with an activating mutation in beta-catenin, and it has been postulated that pituitary stem cells might play a role in oncogenesis in human ACP. Stem cells have also been identified in pituitary adenoma. Our aim was to characterize the expression pattern of ABCG2, CD44, DLL4, NANOG, NOTCH2, POU5F1/OCT4, SOX2, and SOX9 stem cell markers in human ACP and pituitary adenoma. Methods and Results: We studied 33 patients (9 ACP and 24 adenoma) using real- time quantitative PCR (RT-qPCR) and immunohistochemistry. SOX9 was up-regulated in ACP, exhibiting positive immunostaining in the epithelium and stroma, with the highest expression in patients with recurrence. CD44 was overexpressed in ACP as confirmed by immunohistochemistry. SOX2 did not significantly differ among the tumour types. The RT-qPCR array showed an increased expression of MKI67, OCT4/POU5F1, and DLL4 in all tumours. NANOG was decreased in ACP. ABCG2 was down-regulated in most of the tumours. NOTCH2 was significantly decreased in the adenomas. Conclusion: Our results confirm the presence of stem cell markers in human pituitary tumours as well as the different expression patterns of ACP and adenoma. These findings suggest that ACP may originate from a more undifferentiated cell cluster. Additionally, SOX9 immunodetection in the stroma and the highest expression levels related to the relapse of patients suggest a contribution to the aggressive behaviour and high recurrence of this tumour type. (C) 2016 S. Karger AG, Basel.
Palavras-chave
Stem cell markers, Tumour, Pituitary adenoma, Craniopharyngioma
URI
https://observatorio.fm.usp.br/handle/OPI/18016
Referências
  1. Andoniadou CL, 2012, ACTA NEUROPATHOL, V124, P259, DOI 10.1007/s00401-012-0957-9
  2. Andoniadou CL, 2013, CELL STEM CELL, V13, P433, DOI 10.1016/j.stem.2013.07.004
  3. Brastianos PK, 2014, NAT GENET, V46, P161, DOI 10.1038/ng.2868
  4. Cani CMG, 2011, CLINICS, V66, P1849, DOI 10.1590/S1807-59322011001100001
  5. Chen JH, 2005, ENDOCRINOLOGY, V146, P3985, DOI 10.1210/en.2005-0185
  6. Chen JH, 2009, STEM CELLS, V27, P1182, DOI 10.1002/stem.51
  7. Chen LC, 2014, CANCER LETT, V349, P61, DOI 10.1016/j.canlet.2014.03.031
  8. Clark AJ, 2012, J NEUROSURG-PEDIATR, V10, P293, DOI 10.3171/2012.7.PEDS11436
  9. Ee PLR, 2004, MOL CANCER THER, V3, P1577
  10. Fauquier T, 2008, P NATL ACAD SCI USA, V105, P2907, DOI 10.1073/pnas.0707886105
  11. Frank S, 1996, BIOCHEM BIOPH RES CO, V222, P794, DOI 10.1006/bbrc.1996.0823
  12. Gagliano T, 2013, PITUITARY, V16, P91, DOI 10.1007/s11102-012-0380-1
  13. Garcia-Lavandeira M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004815
  14. Garcia-Lavandeira M, 2012, J CLIN ENDOCR METAB, V97, pE80, DOI 10.1210/jc.2011-2187
  15. Gaston-Massuet C, 2011, P NATL ACAD SCI USA, V108, P11482, DOI 10.1073/pnas.1101553108
  16. Gleiberman AS, 2008, P NATL ACAD SCI USA, V105, P6332, DOI 10.1073/pnas.0801644105
  17. Gomes DC, 2015, EUR J ENDOCRINOL, V172, P603, DOI 10.1530/EJE-14-0934
  18. Gunthert U, 1993, Curr Top Microbiol Immunol, V184, P47
  19. Gunthert U, 1996, CURR TOP MICROBIOL, V213, P271
  20. Guzzo MF, 2015, J NEUROENDOCRINOL, V27, P616, DOI 10.1111/jne.12277
  21. Haslam IS, 2011, DRUG METAB DISPOS, V39, P2321, DOI 10.1124/dmd.111.038323
  22. Holsken A, 2014, PITUITARY, V17, P546, DOI 10.1007/s11102-013-0543-8
  23. Jayakody SA, 2012, J CLIN INVEST, V122, P3635, DOI 10.1172/JCI64311
  24. Karavitaki N, 2006, ENDOCR REV, V27, P371, DOI 10.1210/er.2006-0002
  25. Komminoth P, 1996, HISTOCHEM CELL BIOL, V106, P551
  26. Liu W, 2012, CANCER-AM CANCER SOC, V118, P1693, DOI 10.1002/cncr.26483
  27. MCCARTY KS, 1985, ARCH PATHOL LAB MED, V109, P716
  28. Mertens F, 2015, ENDOCR-RELAT CANCER, V22, P481, DOI 10.1530/ERC-14-0546
  29. Oikonomou E, 2005, J NEURO-ONCOL, V73, P205, DOI 10.1007/s11060-004-5232-z
  30. Ouspenskaia T, 2016, CELL, V164, P156, DOI 10.1016/j.cell.2015.11.058
  31. Pan GJ, 2007, CELL RES, V17, P42, DOI 10.1038/sj.cr.7310125
  32. Preda V, 2015, ENDOCR PATHOL, V26, P1, DOI 10.1007/s12022-014-9341-8
  33. Raetzman LT, 2004, DEV BIOL, V265, P329, DOI 10.1016/j.ydbio.2003.09.033
  34. Rizzoti K, 2013, CELL STEM CELL, V13, P419, DOI 10.1016/j.stem.2013.07.006
  35. Salehi F, 2009, NEUROSURGERY, V65, P429, DOI 10.1227/01.NEU.0000349930.66434.82
  36. Sato K, 2006, CLIN NEUROPATHOL, V25, P25
  37. Scott CE, 2010, NAT NEUROSCI, V13, P1181, DOI 10.1038/nn.2646
  38. Sekine S, 2002, AM J PATHOL, V161, P1997, DOI 10.1016/S0002-9440(10)64477-X
  39. Sughrue ME, 2011, PITUITARY, V14, P276, DOI 10.1007/s11102-011-0308-1
  40. Tunici P, 2009, METHODS MOL BIOL, V568, P195, DOI 10.1007/978-1-59745-280-9_12
  41. Vankelecom H, 2010, EUR J NEUROSCI, V32, P2063, DOI 10.1111/j.1460-9568.2010.07523.x
  42. Xing B, 2013, BIOMED ENVIRON SCI, V26, P592, DOI 10.3967/0895-3988.2013.07.011
  43. Xu Q, 2009, BRIT J CANCER, V101, P303, DOI 10.1038/sj.bjc.6605142
  44. Zhu XY, 2006, GENE DEV, V20, P2739, DOI 10.1101/gad.1444706
  45. Zoller M, 2011, NAT REV CANCER, V11, P254, DOI 10.1038/nrc3023

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/14
Carregar mais